Boothbay Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boothbay Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80,543	Closed	-$304K	–	1384
2024 Q4	$304K	Sell	80,543 -4,934	-6%	-$23.2K	0.01%	1063
2024 Q3	$277K	Hold	85,477	–	–	0.01%	1284
2024 Q2	$162K	Sell	85,477 -17,300	-17%	-$33.5K	﹤0.01%	1316
2024 Q1	$292K	Sell	102,777 -116,564	-53%	-$1.52M	0.01%	1198
2023 Q4	$3.23M	Buy	+219,341	New	+$3.36M	0.08%	336
2022 Q3	–	Sell	-34,500	Closed	-$861K	–	2218
2022 Q2	$664K	Sell	34,500 -13,771	-29%	-$163K	0.02%	1024
2022 Q1	$620K	Buy	+48,271	New	+$1.09M	0.01%	1178

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's AMLX Position: Q1 2025 in Review

Boothbay Fund Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 80,543 shares — an estimated $304K sold.

Boothbay Fund Management first reported a position in AMLX in Q1 2022 and held it in 7 quarters. The position peaked at $3.23M in Q4 2023. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

Boothbay Fund Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 80,543 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $304K.
Boothbay Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Boothbay Fund Management's Amylyx Pharmaceuticals position peaked at $3.23M in Q4 2023.
136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.